Fluoroquinolone resistance among Neisseria gonorrhoeae isolates from Shanghai, China: Detection of quinolone resistance-determining region mutations

Indian Journal of Medical Research

Volumn 129, Issue 6, 2009, Pages 701-706

  Tiejun, Zhang ^a,f   Zhou, Xiaoming ^a   Zhang, Jilum ^b   Zhang, Yinghu ^c   Ren, Yanhua ^c   Chen, Yue ^d   Gu, Weiming ^e   Zhang, Tao ^a,f   Jiang, Qingwu ^a,f  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Entry Exit Inspection and Quarantine Bureau   (China)

^c Centre for Disease Control and Prevention of Shanghai   (China)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Shanghai Skin Diseases and Sexually Transmitled Diseases Hospital   (China)

^f BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Fluoroquinolone; gyrA; Neisseria gonorrhoeae; parC; Resistance

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GLYCINE; LOMEFLOXACIN; OFLOXACIN; PHENYLALANINE; PROTEIN PARC; SERINE;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHINA; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; CHINA; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NEISSERIA GONORRHOEAE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA;

EID: 70349557425     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ye SZ. Antibiotics treatment of Neisseria gonorrhoeae. Chin J Dermatol 2003; 36: 296-300.
2. Ye S, Su X, Wang Q, Yin Y, Dai X, Sun H. Surveillance of antibiotic resistance of Neisseria gonorrhoeae isolates in China, 1993-1998. Sex Transm Dis 2002; 29: 242-5.
3. World Health Organization. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacifi c Region, 2006. Commun Dis Intell 2008; 32: 48-51.
4. Goold PC, Bignell CJ. No way back for quinolones in the treatment of gonorrhea. Sex Transm Infect 2006; 82: 225-6.
5. Borgen K, van Loo I, Koedijk F, van de Laar M. Increase of gonococcal quinolone resistance in the Netherlands from 2002-2004. Euro Surveill 2005; 10: E05 117.4.
6. Yang Y, Liao M, Gu WM, Bell K, Wu L, Eng NF, et al. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother 2006; 58: 868-72.
7. Centers for Disease Control and Prevention (CDC). Increases in fl uoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men - United States, 2003 and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 2004; 53: 335-8.
8. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Changing epidemiologic profi le of quinolone-resistant Neisseria gonorrhoeae in London. J Infect Dis 2005; 192: 1191-5.
9. Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 1994; 14: 371-80.
10. Unemo M, Sjöstrand A, Akhras M, Gharizadeh B, Lindbäck E, Pourmand N, et al. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain. APMIS Acta Pathol Microbiol Immunol 2007; 115: 231-41.
11. Uthman A, Heller-Vitouch C, Stary A, Bilina A, Kuchinka- Koch A, Soltz-Szots J, et al. High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes. Sex Transm Dis 2004; 31: 616-8.
12. Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profi les. Antimicrob Agents Chemother 1996; 40: 1020-3.
13. World Health Organization. Sensitivity testing of Neisseria gonorrhoeae: methodologies for use by participations in the WHO Western Pacific Regional Resistance Surveillance Programme. In: WHO/ WPR Regional Antimicrobial Surveillance Working Group Meeting Proceedings. 1992; 1: 33-5.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI 2008; M100-S19.
15. Deguchi T, Yasuda M, Asano M, Tada K, Iwata H, Komeda H, et al. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995; 39: 561-3.
16. Trees DL, Sandul AL, Whittington WL, Knapp JS. Identification of novel mutation patterns in the parC gene of ciprofl oxacin-resistant isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1998; 42: 2103-5.
17. Centers for Disease Control and Prevention. Increases in fl uoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 2002; 51: 1041-4.
18. Sethi S, Sharma D, Mehta SD, Singh B, Smriti M, Kumar B, et al. Emergence of ciprofl oxacin resistant Neisseria gonorrhoeae in north India. Indian J Med Res. 2006; 123: 707-10.
19. Ray K, Bala M, Kumar J, Misra RS. Trend of antimicrobial resistance in Neisseria gonorrhoeae at New Delhi, India. Int J STD AIDS 2000; 11: 115-8.
20. Farhi D, Gerhardt P, Falissard B, Poupet H, Poyart C, Dupin N. Increasing rates of quinolone-resistant Neisseria gonorrhoeae in Paris, France. J Eur Acad Dermatol Venereol. 2007; 21: 818-21.
21. (No author Listed). The Gonococcal Antimicrobial Surveillance Programme (GASP). WHO western Pacific region, 1995. Wkly Epidemiol Rec 1997; 72: 25-7.
22. WHO Western Pacifi c Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2003. Commun Dis Intell 2005; 29: 62-4.
23. Giles JA, Falconio J, Yuenger JD, Zenilman JM, Dan M, Bosh MC. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J Infect Dis 2004; 189: 2085-93.
24. Wang SC, Liu YF, Su MQ, Wang Q. Correlation of in vitro susceptibilities to quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains isolated with changes in gyrA and parC in China. Di4 Jun Yi Da Xue Bao 2001; 22: 2257-61.
25. Kam KM, Kam SS, Cheung DT, Tung VW, Au WF, Cheung MM. Molecular characterization of quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Antimicrob Agents Chemother 2003; 47: 436-9.
26. Zou MX, Xia ZD, Chen SZ, Tang Y, Liu HL, Zhang GQ. Correlation between fl uoroquinolone resistance and mutations of Neisseria gonorrhoeae gyrA and parC genes. Chin J Dermatol 2002; 35: 199-202.
27. Wang B, Xu JS, Wang CX, Mi ZH, Pu YP, Hui M, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae isolated in Jiangsu Province, China, with a focus on fluoroquinolone resistance. J Med Microbiol. 2006; 55: 1251-5.
28. Lindback E, Rahman M, Jalal S, Wretlind B. Mutations in gyrA, gyrB, parC and parE in quinolone-resistant strains of Neisseria gonorrhoeae. Acta Pathol Microbiol et Immunol 2002; 110: 651-7.
29. Shigemura K, Shirakawa T, Okada H, Hinata N, Acharya B, Kinoshita S, et al. Mutations in the gyrA and parC genes and in vitro activities of fl uoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sex Transm Dis 2004; 31: 180-4.